Menu Search
Equities

Yunkang Group Ltd

2325:HKG

Yunkang Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)7.40
  • Today's Change0.40 / 5.71%
  • Shares traded2.96m
  • 1 Year change-38.64%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Yunkang Group Ltd is an investment holding company primarily engaged in the provision of diagnosis testing services. The Company’s service portfolio mainly includes three services. The diagnostic outsourcing services engages in the provision of diagnostic outsourcing services to hospitals, other medical institutions and public health institutions. The diagnostic testing services for medical institution alliances engages in assisting hospitals to establish on-site diagnostic centers through joint collaboration in main disease areas such as infectious diseases, reproductive health, genetic diseases and pathology, and the provision of comprehensive solutions including testing technologies, professional technicians and others to hospitals. The diagnostic testing services for non-medical institutions engages in the provision of personalized diagnostic testing, medical report consultation services and hospital referral services. The Company conducts its business in the domestic market.

  • Revenue in HKD (TTM)853.53m
  • Net income in HKD-297.66m
  • Incorporated2018
  • Employees1.46k
More ▼

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 Jul 202414.50k0.00%
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.